Registration Dossier

Diss Factsheets

Toxicological information

Repeated dose toxicity: dermal

Currently viewing:

Administrative data

Endpoint:
repeated dose toxicity: dermal
Remarks:
other: no data, migrated data set
Type of information:
experimental study
Adequacy of study:
supporting study
Reliability:
4 (not assignable)
Rationale for reliability incl. deficiencies:
other: Original report not yet available, migrated data set

Data source

Reference
Reference Type:
secondary source
Title:
Substituted Anilines Task Force:unpublished draft,72 pages (12.07.1983)
Author:
Du Pont Company Data (no date)
Bibliographic source:
Cited in: Rautio: Synthetic Organic Chemical Manufactures Association

Materials and methods

Principles of method if other than guideline:
Method: other: no data , migrated data set
GLP compliance:
not specified

Test material

Constituent 1
Chemical structure
Reference substance name:
3,4-dichloroaniline
EC Number:
202-448-4
EC Name:
3,4-dichloroaniline
Cas Number:
95-76-1
Molecular formula:
C6H5Cl2N
IUPAC Name:
3,4-dichloroaniline
Details on test material:
IUCLID4 Test substance: no data

Test animals

Species:
rabbit
Strain:
not specified
Sex:
not specified

Administration / exposure

Type of coverage:
not specified
Vehicle:
not specified
Details on exposure:
Route of Administration: dermal
Duration of treatment / exposure:
2 weeks, 6 h/d
Frequency of treatment:
5 d/week
Doses / concentrationsopen allclose all
Remarks:
Doses / Concentrations:
60 mg/kg bw
Basis:

Remarks:
Doses / Concentrations:
135 mg/kg bw
Basis:

No. of animals per sex per dose:
no data
Control animals:
other: no data

Results and discussion

Target system / organ toxicity

Critical effects observed:
not specified

Any other information on results incl. tables

low dose: Skin irritation, no other pathophysiological changes, increase in methemoglobin formation, reduction of erythrocytes and hemoglobin.

high dose: after 6 to 8 days 50 % of the animals were dead, increase in methemoglobin and glutamat pyruvat transaminase,reduction of erythrocytes and hemoglobin.

Applicant's summary and conclusion